

LEADING OFF

TIPS, TRENDS & NEWS YOU CAN USE

ALLERGAN AND PFIZER TO JOIN FORCES

As we go to press, Allergan and Pfizer have entered into a definitive agreement under which Pfizer will merge with Allergan. The combined company will be known as Pfizer plc. Under the agreement, Pfizer will combine with Allergan in a stock transaction currently valued at \$363.63 per Allergan share, for a total enterprise value of approximately \$160 billion based on the closing price of Pfizer common stock of \$32.18 (Nov. 20, 2015).

“The combination of Pfizer and Allergan will create a new biopharmaceutical leader with

leading therapeutic categories, including eye care,” explains Allergan’s CEO, Brent Saunders, who will become the new company’s president and COO, and thus, oversee Pfizer plc’s commercial business, manufacturing and strategy functions. “By combining with Pfizer, we will have an even greater impact on the eye care community by expanding our product offering into more markets globally and having enhanced resources to discover and develop new treatments.”

Pfizer’s Ophthalmology External Research Unit, complements Allergan’s established treatments for dry

eye disease, ocular allergy, post-surgical healing, macular edema post-retinal vein occlusion, uveitis, diabetic macular edema, bacterial conjunctivitis and redness, irritation and swelling from inflammation of the eye. The combined company would include five anti-glaucoma drugs.

In addition, it would have no less than 17 mid-to-late stage development opportunities in eye care, including Tripligan (MMT Ocular hypertension and glaucoma) and cyclosporine ophthalmic emulsion (Restasis in a Multi-Dose Preservative-Free bottle).

JOINT BENEFITS

The merger benefits Pfizer in that Allergan can enhance Pfizer’s R&D capabilities in product line extensions, molecular entities, manufacturing and distribution capabilities, according to a press release about the merger.

“The proposed combination of Pfizer and Allergan will create a leading global pharmaceutical company with the strength to research, discover and deliver more medicines and therapies to more people around the world,” stated Pfizer’s, chairman and CEO Ian Read, in a press release.

NEW COMPANY STRUCTURE

In addition to Mr. Saunders’ move, Pfizer plc’s board will have 15 directors (11 from Pfizer and

Continued on p. 14

TOP 10 EYE-INJURY CAUSING SPORTS

Derrick Rose, Steve Nash, Allan Ray, Jon Scheyer, Eric Katenda and Amare Stoudemire not only share a love of this No. 1 eye-injury-causing sport, they have also contributed to its number:

1. **Basketball: 6,307** estimated injuries
2. **Water and pool activities: 5,505** estimated injuries
3. **Guns (air, gas, spring and BB): 2,397** estimated injuries
4. **Baseball/softball: 2,100** estimated injuries
5. **Football: 1,726** estimated injuries
6. **Bicycles: 1,483** estimated injuries
7. **Soccer: 1,338** estimated injuries
8. **Health club (exercise/weightlifting): 1,325** estimated injuries
9. **Fishing: 1,183** estimated injuries
10. **Table or air hockey: 1,180** estimated injuries

Courtesy: Prevent Blindness